Artesian Subscribes to Gene Logic's GeneExpress CVS DataSuite™

18-Mar-2002

GAITHERSBURG, Md., Mar 14, 2002 (BW HealthWire) -- Gene Logic Inc. , a leading provider of genomics-based information products and services, announced today that Artesian Therapeutics, Inc., a privately held biopharmaceutical company, has subscribed to Gene Logic's GeneExpress Cardiovascular (CVS) DataSuite(TM), for use as a primary reference source in Artesian's drug discovery and development efforts in cardiovascular disease.

Financial details of the multiyear subscription agreement were not disclosed. Gene Logic's GeneExpress(R) Cardiovascular Program and the resulting GeneExpress CVS DataSuite(TM) stem from the Company's disease focused initiatives to create genomic information products related to critical disease indications of interest to the pharmaceutical and biotechnology communities. The CVS Program is focused on creating an information product comprised of a comprehensive survey of normal and diseased human cardiac and vascular tissues from a broad cross-section of individuals, races, medication regimens, lifestyles, disease stages and other demographic and clinical parameters.

The Cardiovascular DataSuite(TM) contains representative samples from key cardiac and vascular disease states including atherosclerosis, coronary artery disease, hypertension, congestive heart failure, stroke, peripheral vascular disease, arteriopathies, venous thrombosis and arrhythmia. Over time, it is anticipated to also contain relevant in vitro and in vivo disease animal model systems related to cardiovascular indications, which will provide a critical basis for comparison between non-human and human disease models.

Based upon the quality of samples and the corresponding data contained in the Cardiovascular DataSuite(TM), researchers will be able to use this product to identify and prioritize potential drug targets, as well as identify surrogate markers for progression of cardiovascular diseases. The CVS DataSuite(TM) also allows for identification of overlapping expression patterns, which may indicate common pathways across multiple cardiovascular diseases, which can enable researchers to discover alternative targets for existing drugs, as well as prioritize multiple potential drug targets.

https://www.bionity.com/en/news/9445/artesian-subscribes-to-gene-logic-s-geneexpress-cvs-datasuite.html